Compounded & telehealth

Telehealth Services for GLP-1 Prescriptions: How They Compare

A factual, side-by-side look at the major US telehealth services that prescribe GLP-1 medications, what each one actually sells, what it costs all-in, and which ones have regulatory history worth knowing about.

Last verified September 14, 2026·18 sources cited

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

Disclosure: this site is affiliate-supported and may earn a commission if you sign up with some of the companies named here. That does not change what appears below. Every price, regulatory action, and lawsuit is sourced, and companies we have no commercial relationship with are included on the same terms.

There are dozens of ways to get a GLP-1 prescription online now, and they are not interchangeable. The difference that matters most is not price. It is what the company actually sells: an FDA-approved branded medication, a compounded copy, or a clinical service that bills your insurance.

This guide sorts them by that distinction, gives the cost structure for each, and flags the regulatory history where there is any. It is not medical advice, and nothing here says which medication or dose is right for anyone.

How should I think about the categories?

Branded-only platforms prescribe FDA-approved Wegovy, Ozempic, Zepbound, or Foundayo and fill through a licensed pharmacy or a manufacturer channel. You pay a membership or visit fee plus the medication price.

Compounded platforms sell semaglutide or tirzepatide mixed by a compounding pharmacy. These are not FDA-approved products. Since the shortage ended in February 2025, these operate under a narrow patient-specific exception, and several have drawn FDA warning letters or manufacturer lawsuits.

Insurance-first clinical practices bill your health plan for visits and work on prior authorization. Slower to start, usually the cheapest if your plan covers the drug.

Manufacturer direct channels are not telehealth at all, but you can pair them with a cheap visit. NovoCare Pharmacy sells Wegovy pens at $349 a month and Wegovy tablets from $149; LillyDirect sells Zepbound vials from $299.

Both manufacturers publish lists of telehealth companies they recognize. This is useful signal, though neither endorses the clinicians.

Novo Nordisk’s list of recognized telehealth providers includes 9amHealth, eMed, Form Health, knownwell, LifeMD, Ro, Sesame, and WeightWatchers, describing them as recognized for legitimate medicine sourcing and patient support [1].

LillyDirect’s obesity telehealth page lists General Medicine ($25 average insured visit; self-pay quoted at either $30 or $100 — see below), Counsel Health ($29 per visit, $25 a month annually), Sesame ($99 a month, $59 annually), WeightWatchers ($149 a month, $74 annually), and knownwell ($31 average insured visit, $299 self-pay) [2] (verified 2026-09-14). One caution on that list: Lilly’s own two pages disagree on General Medicine’s self-pay visit fee, with lilly.com/find-care/telehealth/obesity printing $30 per chat visit and lillydirect.com/pharmacy-solutions printing $100 per visit for the identical listing. General Medicine’s own site publishes no self-pay visit price, so treat it as a range rather than a number.

Notice what is missing from both lists: every platform whose business was built on compounded product.

Branded-only platforms

Ro (Ro Body)

Ro was one of the three original NovoCare Pharmacy telehealth partners in April 2025 and, unlike Hims, kept the relationship. It sells branded Wegovy injection, the Wegovy pill, and Zepbound, and has exited compounded semaglutide entirely.

Cost structure: $39 first month then $149 a month for the Ro Body membership, or $888 prepaid for a year. Medication is separate, starting around $149 for the Wegovy pill, $199 for the Wegovy pen, and $299 for Zepbound, with longer subscription terms reducing the monthly medication price [3]. With covered commercial insurance plus a manufacturer savings card, the medication can drop to roughly $25 a month.

Available in all 50 states. No FDA warning letter identified.

Hims & Hers

The most-watched company in this category, and the one with the longest regulatory record. Hims launched compounded semaglutide in May 2024, aired a Super Bowl ad in February 2025 that drew a bipartisan Senate letter, received an FDA warning letter in September 2025, lost its Novo partnership in June 2025, launched and withdrew a $49 compounded semaglutide pill in February 2026, was sued by Novo for patent infringement, and settled in March 2026 by agreeing to stop advertising compounded GLP-1s and to sell branded Wegovy and Ozempic.

It is now effectively a branded platform. The company disclosed an SEC investigation into its statements about compounded semaglutide in its fiscal 2025 Form 10-K, and HHS referred it to the Department of Justice in February 2026. Separately, and not about compounding at all, the FTC — joined by the State of Utah and Los Angeles County — sued Hims & Hers on July 29, 2026 in the Northern District of California, alleging that it enrolled customers in auto-renewing subscriptions without adequate disclosure, made cancellation difficult, and shared health data with advertising platforms. Hims denies the allegations and is defending the case [20][21]. (updated 2026-09-14) Q2 2026 revenue was about $753 million with 2.89 million subscribers across all categories [4].

Cost structure varies by plan and dose and has changed repeatedly through 2026. Verify on hims.com before committing; do not rely on a price you read in a review, including this one.

We cover the full sequence in a separate article, Hims & Hers semaglutide: what happened.

LifeMD

Another original NovoCare partner and still on Novo’s recognized list [1]. Offers branded Wegovy injection and pill, Ozempic, Zepbound, and Saxenda, with insurance support. Independent 2026 comparisons placed LifeMD among the higher all-in cash costs, so check the total before assuming the advertised entry price is what you pay.

Amazon One Medical

Launched April 21, 2026. Every medication in the program is an FDA-approved branded product from Novo Nordisk or Eli Lilly, delivered through Amazon Pharmacy. Cash-pay oral products start at $149 a month and injectables at $299, with insured pricing starting as low as $25. Same-day delivery was available in nearly 3,000 U.S. cities at launch, with expansion to about 4,500 planned by the end of 2026 [5].

The distinguishing feature is integration with primary care rather than a standalone weight program.

Sesame and the Costco program

Sesame is a cash-pay clinician marketplace. Through Costco it runs Success by Sesame: a $99 a month membership, or $59 a month annually, with a further discount for Costco members. Members with a prescription can buy Wegovy or Ozempic injections at Costco Pharmacy for $349 a month, about half the usual cash price, with $199 a month for the first two months for qualifying new patients. The Wegovy pill runs as low as $149 [6].

A Costco membership is required. All-in for the injection lands near $408 a month at the ongoing rate.

WeightWatchers Clinic

WW acquired Sequence in March 2023 for about $132 million, filed Chapter 11 in May 2025 under roughly $1.6 billion of debt, and emerged about six weeks later having cut around $1.15 billion of it. The clinical GLP-1 business never stopped operating and has become the company’s growth engine.

Listed on LillyDirect at $149 a month, or $74 a month annually, medication separate [2]. Also on Novo’s recognized list [1].

Insurance-first clinical practices

knownwell

A weight-inclusive primary care and obesity medicine practice, virtual and in person. Average cost per visit with insurance is $31; self-pay is $299 per visit [2]. It accepts commercial insurance and Medicare and markets a pathway tied to CMS’s Medicare GLP-1 Bridge Program, which began July 1, 2026 and gives qualifying Part D beneficiaries a $50 monthly copay on Wegovy, the Zepbound KwikPen, or Foundayo through December 31, 2027 [7][16].

If you have coverage, this category is almost always cheaper than any cash-pay option.

Form Health

A virtual obesity medicine practice staffed by board-certified obesity medicine physicians and registered dietitians, built around insurance rather than cash-pay compounded product. On Novo’s recognized list [1].

PlushCare

Broad telehealth with a $19.99 monthly membership, visits billed to insurance. Available in all 50 states. Stopped accepting Medicare Part B as of January 1, 2026.

Teladoc Health

The largest publicly traded virtual care company in the country, reaching GLP-1 patients mainly through employer and health plan contracts rather than a consumer cash product. That business model kept it out of the compounding enforcement wave entirely.

9amHealth, eMed, General Medicine, Counsel Health

Four lower-profile options on the manufacturer lists — 9amHealth and eMed are on NovoCare’s recognized list, General Medicine and Counsel Health on Lilly’s. Counsel Health is the cheapest verified route on either list if you already know you want a branded prescription and do not need a full program wrapped around it: its own site confirms $29 per visit, or $300 a year for unlimited visits, with labs billed separately at about $18 in most states and $43 in New York and New Jersey (verified 2026-09-14). General Medicine’s insured visits average $25, but its self-pay visit fee is not something we can state as a number, for the reason given above [2].

Platforms that still sell compounded product

These operate under the narrow patient-specific pathway described in our legal explainer. FDA’s own guidance warns telehealth companies against calling compounded drugs generic, equivalent, or FDA-approved [8], so read the marketing copy critically.

Mochi Health

Sells compounded semaglutide injection, a compounded semaglutide pill, and compounded tirzepatide. Reported mid-2026 pricing: $79 a month membership ($39 first month in eligible states), with compounded semaglutide at $99 for four weekly doses and compounded tirzepatide at $199 [9].

Eli Lilly sued Mochi in April 2025, alleging it advertised mass-produced compounded tirzepatide as personalized and violated California’s corporate practice of medicine law by influencing dosing and formulation [10]. On April 20, 2026 a judge in the Northern District of California allowed Lilly’s amended false-advertising claims against Mochi to proceed. On September 8, 2026 the same judge trimmed the case again on the second amended complaint, dismissing the Lanham Act conspiracy claims against the Mochi medical defendants and the supplying pharmacy while allowing California unfair-competition conspiracy claims against Aequita Pharmacy and its parent to go forward [18]. Separately, a September 4, 2026 investigation reported that Washington State inspectors shut down Aequita Pharmacy, Mochi’s former in-house compounder, citing a serious risk to patients and GLP-1 base powder said to have been imported illegally, and documented three patient injury or death lawsuits involving pharmacies in Mochi’s supplier network [19]. (updated 2026-09-14)

Mochi runs an affiliate partner program; third-party sources describe roughly 20 percent of a referred user’s subscription fee for the first year.

Henry Meds

Compounded semaglutide and tirzepatide at flat monthly pricing. Also an April 2025 Lilly defendant. On September 24, 2025 the court allowed Lilly’s claim that Henry falsely advertises its compounded GLP-1s as personalized or patient-specific to proceed, while dismissing the broader safe-and-effective claim. No public settlement as of September 2026.

MEDVi

Grew extremely fast. The New York Times profiled it on April 2, 2026 as an AI-built startup with two employees, reporting about $401 million of 2025 revenue, 250,000 customers, and a projection of $1.8 billion in 2026 sales. Treat those numbers as company-supplied: MEDVi is a private Delaware LLC with no public filings, and the figures rest on financials it showed the Times rather than on an audit.

Six weeks before that profile, on February 20, 2026, FDA sent a warning letter addressed to “MEDVi, LLC dba MEDVi” saying its website labeling implied MEDVi was the compounder when it is not, and citing “Same active ingredient as Wegovy and Ozempic” and “Same active ingredient as Mounjaro and Zepbound” claims as false or misleading [11]. In an April 8, 2026 statement the company said it had “never received a letter from the FDA” and that the cited site belonged to an affiliate marketing agency; the letter on FDA’s site is nonetheless addressed to MEDVi, LLC and cites MEDVi-branded claims. Both positions are on the public record and readers can compare them directly.

Ivim Health

A hybrid in-person and virtual model with a $75 monthly membership and compounded semaglutide priced around $75 a month on a 12-month prepay or $100 on a six-month prepay [12]. FDA issued a warning letter to Ivim Services LLC dba Ivim (letter 721816) dated February 20, 2026, citing false or misleading website claims that made its compounded semaglutide and tirzepatide products misbranded [17].

Note the prepay structure: those low monthly figures require paying for six or twelve months up front.

Zealthy

Membership at $135 a month plus medication, with reported 2026 compounded semaglutide pricing around $149 to $151 a month and compounded tirzepatide from $216 to $329 depending on plan length. Independent reviewers repeatedly flag that the total is easy to misread on the marketing pages. All-in lands near $286 a month for semaglutide.

Eden, Noom Med, Found, Brello Health

Four more platforms with compounded offerings. Noom Med discloses on its own pages that the compounded semaglutide it offers is made in an FDA-registered facility but has not been reviewed by FDA for safety, efficacy, or quality, and offers a microdose plan. Found bundles the visit, prescription, medication, and shipping into one monthly price. Brello pairs compounded GLP-1s with vitamin B6 and bills every 10 weeks rather than every three months, which is an easy thing to misread.

The five questions that actually decide cost

Is there a membership fee on top of the medication? Membership fees in this market run from $19.99 to $149 a month. Always add them.
Is the low price a prepay price? Twelve-month prepay pricing is common and usually non-refundable.
Does the price hold as the dose goes up? Some platforms charge a flat rate across the dose ladder; others escalate. Ask before you start.
Are labs, shipping, and supplies included?
How do you cancel? The FTC’s December 2025 final order against NextMed carried a $150,000 judgment and required clear disclosure of refund and cancellation terms, simple cancellation, and informed consent before billing [13]. That order exists because these practices were common.

A note on how to read reviews, including this one

The FTC’s rule on consumer reviews and testimonials, 16 CFR Part 465, took effect October 21, 2024. It bans fake and AI-generated reviews, insider reviews without disclosure, and presenting a site you control as an independent review source. It also requires disclosure of material connections such as affiliate commissions.

Apply that standard when you read comparisons. If a page ranks providers without saying whether it earns commissions, or reproduces a provider’s “same active ingredient as Ozempic” copy, both of those are problems — the second is language FDA has formally cited as false or misleading [8].

Sources

Questions people ask

What is the cheapest way to get a GLP-1 through telehealth?

Coverage through insurance or Medicare is almost always cheapest when you qualify, with copays as low as $25 and a $50 Medicare copay under the Medicare GLP-1 Bridge Program, which began July 1, 2026 and is scheduled to run through December 31, 2027 (verified 2026-09-14). Both of those are program or savings-card tiers for people who qualify, not cash prices. Among cash-pay routes, starter doses of the Wegovy pill at $149 a month plus a low visit fee is currently the least expensive branded path.

Do any telehealth services still sell compounded semaglutide?

Some do, under a narrow patient-specific pathway, including Mochi Health, Ivim Health, Eden, Zealthy, Noom Med, and Found. Several of these companies have received FDA warning letters or are defendants in manufacturer lawsuits, which is worth knowing before you sign up.

Which telehealth companies are recognized by the drug manufacturers?

Novo Nordisk lists 9amHealth, eMed, Form Health, knownwell, LifeMD, Ro, Sesame, and WeightWatchers. LillyDirect lists General Medicine, Counsel Health, Sesame, WeightWatchers, and knownwell. Being listed means the manufacturer recognizes the source of medicine, not that it endorses the clinicians.

Why is the advertised price never the price I pay?

Most platforms separate a membership or visit fee from the medication cost. A $149 medication plus a $135 membership is a $284 month. The FTC's 2025 order against NextMed was partly about exactly this kind of undisclosed cost.

Does telehealth work in every state?

The prescriber must be licensed in the state where you are physically located during the visit. Most large platforms cover all 50 states, but some smaller ones do not, and a minority of states require a live video visit rather than a questionnaire.

Can telehealth companies get my insurance to cover a GLP-1?

Some, like Form Health, knownwell, PlushCare, and Teladoc, are built around insurance billing and prior authorization support. Most cash-pay compounded platforms are not.

How do I cancel one of these subscriptions?

Check the cancellation terms before you enroll, not after. Difficult cancellation and auto-renewal were central to the FTC's NextMed order, and prepaid multi-month plans usually cannot be refunded on a pro-rata basis.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.